From the Journals: JBC
Nuclear actin affects transcription elongation. Proteostasis in Alzheimer’s disease. RNA and splicing affect cancer invasiveness. Read about papers on these topics recently published in the Journal of Biological Chemistry.
Nuclear actin affects transcription elongation
Monomeric actin assembles to form long filaments that regulate cell mobility and division, but actin monomers are also important in some nuclear processes, including chromatin remodeling and gene expression. For example, actin is involved in the pause–release of Polymerase II, or Pol II, in which the positive transcription elongation factor b, or P-TEFb, interacts with Pol II to promote transcription elongation. Actin also frequently co-immunoprecipitates with Pol II. However, scientists have not yet characterized the direct binding partners that mediate actin–RNA polymerase interactions.

To catalog actin-binding proteins within the nucleus, Salla Kyher枚inen and colleagues at the University of Helsinki, Finland, used chromatin immunoprecipitation followed by deep sequencing in a . Their results, published in the Journal of Biological Chemistry, indicated that actin associates with genes only upon active transcription elongation. They also found that monomeric actin does not directly bind Pol II but rather binds the P-TEFb subunit Cdk9, which also co-immunoprecipitates with RNA polymerases. They demonstrated that this binding is independent of Cdk9’s kinase activity, although at high concentrations actin does modestly affect this kinase activity.
These findings provide novel insights into the mechanisms by which actin can facilitate transcription. However, while these results suggest actin binding is important for pause–release and transcription elongation, researchers have yet to determine the mechanism by which the actin–Cdk9 interaction affects this process. In addition, scientists still don’t know whether this interaction involves recruiting the P-TEFb complex to Pol II or influences the kinase activity of Cdk9. Researchers will need to perform detailed biochemical analyses in the future to elucidate the precise steps at which actin affects transcription elongation rate.
Proteostasis in Alzheimer’s disease
Alzheimer’s disease, or AD, is a neurodegenerative disorder characterized by dysregulation of the amyloid-beta protein and the amyloid precursor protein, or APP. AD patients frequently present with deposits, or plaques, of aggregated amyloid β, indicating protein quality control issues such as aberrant synthesis, misfolding and inefficient degradation. Most AD research focuses on the expression of APP and posttranslational cleavage of APP to form amyloid β; however, investigating ribosome-associated quality control before APP cleavage could provide researchers with new avenues for understanding AD pathogenesis.
In their in the Journal of Biological Chemistry, Yu Li and colleagues at Shandong University in China used fruit flies expressing mutant APP that accumulates in the endoplasmic reticulum to identify novel factors and molecular mechanisms that regulate APP quality control. In their genetic screen, they found that deletion of RACK1, encoding a protein that associates with the ribosome for translational control, and overexpression of IRE1, a key sensor of the unfolded protein response, reduced levels of mutant APP. Furthermore, they also showed that IRE1-dependent changes depended on the ATPase VCP, a protein that helps degrade polypeptides at stalled ribosomes, and Hrd1, an E3 ubiquitin ligase. Researchers already knew that both VCP and Hrd1 regulate the expression and toxicity of non-mutant APP. Therefore, these results emphasize their role in APP quality control and homeostasis.
This study demonstrated a link between the ribosome-associated quality control pathway and APP proteostasis. Future studies could identify novel therapeutic targets among these molecules to reduce APP-associated neurodegeneration.
RNA and splicing affect cancer invasiveness
Tandem repeats in pericentromeric regions, such as those that make up human satellite II, or HSATII, can be aberrantly transcribed in cancers, such as epithelial and pancreatic cancer. Furthermore, genetic dysregulation in these cancer tissues often promotes double-stranded HSATII RNA, or dsHSATII. However, research has shown that double-stranded RNAs can both promote and suppress tumors. In addition, researchers do not yet know how dsHSATII affects tumor progression.
In their in the Journal of Biological Chemistry, Takuma Iwata and colleagues at the University of Tokyo investigated the function of dsHSATII in pancreatic cancer. They found that dsHSATII RNA promotes mesenchymal-like morphological changes and enhances the invasiveness of pancreatic cancer cells. In addition, they identified an RNA-binding protein, spermatid perinuclear RNA-binding protein, or STRBP, that preferentially binds to dsHSATII over single-stranded HSATII. STRBP is also involved in the alternative splicing of genes associated with the epithelial–mesenchymal transition, or EMT. Using 3D cell cultures and xenograft models, the authors demonstrated that STRBP suppresses dsHSATII’s role in EMT by altering the expression of CLSTN1, an EMT-associated gene that encodes for a transmembrane protein with activity as a cell adhesion molecule. An isoform of CLSTN1 is associated with metastasis and poor prognosis for certain types of cancer.
These results reveal that the novel dsHSATII–STRBP signaling axis regulates EMT in pancreatic cancer. Researchers will need to do more studies in the future to investigate the mechanistic details of this signaling axis and whether STRBP regulates additional genes or could be a novel therapeutic target.
Enjoy reading 91影库Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91影库Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17鈥21 in Cambridge, Massachusetts.